Alkem Laboratories (ALKEM) | Stock Overview & Key Data
Alkem Laboratories Performance Comparison
Stock Range
Today's Range
Low: ₹5,240.00
High: ₹5,400.00
on August 13, 2025
52 Week Range
Low: ₹4,491.65
High: ₹6,439.90
on February 28, 2025
on September 13, 2024
All-Time High: ₹6,439.90 on September 9, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR569.6B
EPS
181.03
P/E Ratio (TTM)
26.32
Forward P/E
22.27
P/B Ratio
4.75
PEG Ratio
22.27
Div. Yield
0.87%
ROE
19.14%
Beta
0.342
Debt to Equity
11.11
Financial Highlights
Profitability
Gross Margin
59.31%
Operating Margin
8.77%
Profit Margin
16.70%
Returns and Earnings
Return on Assets (TTM)
8.09%
Return on Equity (TTM)
19.14%
EBITDA
INR30.1B
Net Income (TTM)
INR21.7B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR1,084.31
Quarterly Revenue Growth (YoY)
7.10%
Quarterly Earnings Growth (YoY)
4.20%
Dividend Information
Last 12-Month Dividend
₹42.00
Current Dividend Yield
0.87%
3-Year Average Dividend Yield
0.45%
3-Year Average Annual Dividend
₹38.67
3-Year Total Dividends
₹116.00
Ex-Dividend Date
February 14, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Alkem Laboratories ALKEM | 569.61B Large-cap | 4.63% | 6.37% | 2.56% | 9.35% | -7.57% | -9.38% | 75.38% | 81.03% |
| Sun Pharmaceutical SUNPHARMA | 3.81T Large-cap | -0.61% | -3.59% | -3.80% | -4.23% | -14.17% | -7.71% | 78.44% | 202.13% |
| Divi's Laboratories DIVISLAB | 1.59T Large-cap | -6.99% | -12.06% | 0.32% | -0.15% | -1.84% | 28.64% | 61.27% | 83.57% |
| Torrent TORNTPHARM | 1.21T Large-cap | 1.03% | 6.50% | 12.00% | 18.50% | 6.07% | 7.97% | 134.32% | 27.94% |
| Cipla CIPLA | 1.20T Large-cap | 1.45% | 2.53% | 0.66% | 5.00% | 2.85% | 5.70% | 47.71% | 100.01% |
| Dr. Reddy's DRREDDY | 1.02T Large-cap | 0.45% | -2.42% | 2.07% | 0.37% | -10.86% | -10.19% | 45.14% | 35.90% |
Ownership & Short Interest
Insider Ownership
67.25%
Institutional Ownership
21.93%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
93K
Average 90-Day Volume
110K
Alkem Laboratories Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Alkem Laboratories would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ALKEM's 52-week high and low?
- In the last 52 weeks, Alkem Laboratories reached a high of ₹6,439.90 (on September 13, 2024) and a low of ₹4,491.65 (on February 28, 2025).
- What is the market cap and P/E ratio for ALKEM?
- Curious about Alkem Laboratories's size and valuation? Its market capitalization stands at 569.61B. When it comes to valuation, the P/E ratio (trailing twelve months) is 26.32, and the forward P/E (looking ahead) is 22.27.
- Does ALKEM pay dividends? If so, what's the yield?
- Yes, Alkem Laboratories is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.87%, and the company has paid an average of ₹38.67 per share annually over the past 3 years.
- Who are Alkem Laboratories's main competitors or similar companies to consider before investing?
When looking at Alkem Laboratories, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.81T Healthcare Drug Manufacturers - Specialty & Generic -7.71% 78.44% Divi's Laboratories
DIVISLAB1.59T Healthcare Drug Manufacturers - Specialty & Generic 28.64% 61.27% Torrent
TORNTPHARM1.21T Healthcare Drug Manufacturers - Specialty & Generic 7.97% 134.32% Cipla
CIPLA1.20T Healthcare Drug Manufacturers - Specialty & Generic 5.70% 47.71% Dr. Reddy's
DRREDDY1.02T Healthcare Drug Manufacturers - Specialty & Generic -10.19% 45.14% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Alkem Laboratories Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Alkem Laboratories's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 19.14%, the Debt to Equity ratio from the most recent quarter is 11.11, and its Gross Profit Margin stands at 59.31%.
- What is the recent revenue and earnings growth for ALKEM?
- Looking at Alkem Laboratories's growth, its revenue over the trailing twelve months (TTM) was INR130B. Compared to the same quarter last year (YoY), quarterly revenue grew by 7.10%, and quarterly earnings saw a YoY growth of 4.20%.
- How much of ALKEM stock is held by insiders and institutions?
- Wondering who owns Alkem Laboratories stock? Company insiders (like executives and directors) hold about 67.25% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 21.93%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.